OBR Daily Commentary

forumImage

2019 Physician Fee Schedule and Quality Payment Program Proposed Rules Released

(ASCO in Action) July 13, 2018 - The Centers for Medicare & Medicaid Services (CMS) released its proposed rule for 2019 Medicare physician reimbursement. CMS estimates that in 2019, overall impact for the hematology/oncology specialty will be a -4 percent reduction in reimbursement and -2 percent for radiation/oncology.

Read Article arrow

Winston Wong, PharmD (Posted: July 17, 2018)

quotesOne has to wonder if the move to reimburse new drugs at WAC+3% will be an indicator of the all drugs being reimbursed at ASP +3%. What is unclear is what then is the resultant reimbursement, if there is a change, due to the sequestration removal?quotes

Add Comment 1 Comment
forumImage

Drugmakers Cancel Price Hikes After California Law Takes Effect

(Bloomberg) July 10, 2018 - A handful of the world’s biggest drugmakers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs.

Read Article arrow

Winston Wong, PharmD (Posted: July 17, 2018)

quotesI really have to wonder just how effective transparency laws are, given that there have been transparency laws pass years ago governing the PBM industry, and nothing seemed to change. The easy example is the Pharmacy GAG requirements.quotes

Add Comment 1 Comment
forumImage

Oncologists Disagree On Use Of Value To Guide Cancer Treatments

(Stanford Medicine/Scope blog) Apr 4, 2018 - A new study found that oncologists have divergent views on how to use “value” to guide cancer treatment recommendations.

Read Article arrow

Winston Wong, PharmD (Posted: July 11, 2018)

quotesThe disagreement on how to define "value" goes far beyond that of the Oncologist. I think the most significant statement made was at the very end where the author stated that no one can agreement on what the definition of value is. hence we are all just chasing a concept that is yet to be defined.quotes

Add Comment 4 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...